Preview

Медицинский Совет

Расширенный поиск

Модифицируемые факторы риска и современные подходы к терапии деменции

https://doi.org/10.21518/2079-701X-2015-10-28-33

Полный текст:

Аннотация

Проблема деменции приобретает все большую социальную и медицинскую значимость в современном мире. По данным ВОЗ, во всем мире в 2010 г. было зарегистрировано 35,6 млн больных демен-цией, сегодня их число оценивается как 44 млн [1]. К 2030 г. количество больных удвоится и достигнет 65,7 млн человек, а к 2050 г. - 115,4 млн [2]. Среди причин развития когнитивного дефицита лидирующее положение занимают цереброваскулярные и нейродегенеративные поражения мозга. Наиболее часто причиной развития деменции является болезнь Альцгеймера (60-70% случаев), второе место отводится сосудистой деменции. Учитывая масштаб этой эпидемии и трудности терапии, важно рассмотреть факторы, коррекция которых позволит уменьшить риск или отсрочить наступление болезни.

Об авторе

А. Н. Боголепова
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Россия


Список литературы

1. Dementia and Risk Reduction. An analysis of protective and modifiable factors. World Alzheimer Report, 2014.

2. Доклад ВОЗ. Деменция: приоритет общественного здравоохранения. 2013. www. who.int.

3. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Munoz Sanchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: asystem-atic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry, 2015. 30(3): 234-46.

4. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews, 2009. Issue 4. Art. No.: CD004034.

5. Oiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol, 2005. 4(8): 487-99.

6. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag, 2008. 4(2): 363-81.

7. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. The Lancet Neurology, 2011. 10(9): 819828.

8. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999. 53(9): 1937-1942.

9. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology, 2004. 63(4): 658-663.

10. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One, 2009. 4(1): 4144.

11. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, Perry G, Smith MA, Zhu X, Moreira PI. Insulin is a two-edged knife on the brain. JAlzheimers Dis, 2009. 18(3): 483-507.

12. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemio-logical perspective. Eur J Pharmacol, 2008. 585(1):.119-29.

13. Kivipelto M, Ngandu T, Fratiglioni L, etal. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol, 2005. 62: 1556-1560.

14. Gorospe EC, Dave JK. The risk of dementia with increased body mass index. Age Ageing, 2007. 36: 23-29.

15. Bruehl H, Wolf OT, Sweat V, et al. Modifiers of cognitive function and brain structure in mid-dleagedand elderly individuals with type 2 diabetes mellitus. Brain Res, 2009. 1280: 186-194.

16. Debette S, Beiser A, Hoffmann U, De Carli Ch et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol, 2010. 68(2): 136-144.

17. Боголепова А.Н., Семушкина Е.П Кардиальные нарушения и когнитивная дисфункция у больных хронической ишемией мозга. Журнал неврологии и психиатрии им. С.С. Корсакова, 2013. 113: 2: 9-13.

18. Yaffe K. Metabolic Syndrome and Cognitive Disorders. Is the Sum Greater Than Its Parts? Alzheimer Dis Assoc Disord, 2007. 21(2): 167-171.

19. Ho YS, Yang X, Yeung SC et al. Cigarette smoking accelerated brain aging and induced pre-Alzheimer-like neuropathology in rats. PloS one, 2012. 7(5): e36752.

20. Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat Commun, 2013. 4: 1495.

21. Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues in clinical neuroscience, 2008. 10(3): 345-57.

22. Yu W-K, Chen Y-T, Wang S-J, Kuo S-C, Shia B-C, Liu C J-L. Cataract surgery is associated with a reduced risk of dementia: a nationwide population-based cohort study. European Journal of Neurology, 2014, Article first published online: 7 SEP 2014, DOI: 10.1111/ene.12561.

23. Chang W-P, Liu M-E, Chang W-Ch et al. Sleep Apnea and the Risk of Dementia: A Population-Based 5-Year Follow-Up Study in Taiwan. PLoS ONE, 2013. 8(10): e78655.

24. Exalto LG, Ouesenberry ChP, Barnes D, Kivipelto M, Jan Biessels G, Whitmer RA. Midlife risk score for the prediction of dementia four decades later. Alzheimer's & Dementia, 2013, 1-9.

25. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology, 2012.; 78: 1323-1329.

26. Ngandu T, Lehtisalo J, Solomon A et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet, 2015. 385(9984): 225563.

27. Norton S, Matthews F, Barnes D, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. The Lancet Neurology, 2014. 13:8: 788-794.

28. Farrow M. User Perceptions of a Dementia Risk Reduction Website and Its Promotion of Behavior Change. JMIR Res Protoc. 2013. 2(1): e15.

29. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, La Ferla FM Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol, 2010. 176: 870-880.

30. Jiang J1, Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. Neurol Sci, 2015. Apr 22 [Epub a head of print].

31. McShane R, AreosaSastre A, Minakaran N. Memantine for dementia. The Cochrane database of systematic reviews. 2006. (2): CD003154.

32. Matsunaga S, Kishi T, Iwata N Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2015. 10(4): e0123289.

33. Schulz JB et al. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of 16-week open-label trial. Journal of Alzheimer's Disease, 2011. 24: 1-13.

34. Cumbo E, Ligori LD. Differential Effects of Current Specific Treatments on Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease: АI2-month, randomized, open-label trial. JоumаI of Alzheimer's Disease, 2014. 39: 417-485.

35. Zhang N1, Wei C, Du H, Shi FD, Cheng Y. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. Dement Geriatr Cogn Disord, 2015. 40(1-2): 85-93.

36. Gauthier S et al. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychology, 2007. 23: 537-545.


Просмотров: 87


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)